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Clinical and diagnostic laboratories often encounter patient sera containing antinuclear anti-
bodies (ANAs) that produce a nuclear dense fine speckled immunofluorescence pattern on
HEp-2 cells.These autoantibodies usually target the dense fine speckled protein of 70 kDa
(DFS70), commonly known as lens epithelium-derived growth factor p75 (LEDGFp75).
Anti-DFS70/LEDGFp75 autoantibodies have recently attracted much interest because of
their relatively common occurrence in sera from patients with positive ANA tests with no
clinical evidence of systemic autoimmune rheumatic disease (SARD). Their presence has
been documented primarily in patients with diverse non-SARD inflammatory conditions
and “apparently healthy” individuals. While there is circumstantial evidence that depend-
ing on the context these autoantibodies could play protective, pathogenic, or sensor roles,
their significance remains elusive. DFS70/LEDGFp75 has emerged during the past decade
as a stress transcription co-activator relevant to HIV integration, cancer, and inflammation.
It is not clear, however, what makes this protein the target of such a common autoantibody
response. We suggest that a better understanding of DFS70/LEDGFp75 biology is key to
elucidating the significance of its associated autoantibodies. Here, we discuss briefly our
current understanding of this enigmatic autoantigen and potential scenarios leading to its
targeting by the immune system.
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INTRODUCTION
The clinical and biological significance of anti-DFS70/LEDGFp75
autoantibodies has been puzzling because in spite of being rel-
atively common and capable of reaching high titers, they lack
disease specificity and can be found in “apparently healthy” indi-
viduals and in patients with diverse non-SARD inflammatory
conditions (1–7). These autoantibodies are present at very low fre-
quencies in patients with systemic autoimmune rheumatic disease
(SARD), and their prevalence appears to be higher in “apparently
healthy” individuals than in these patients (1, 4–7). When present
in SARD patients, these autoantibodies are usually accompanied
by other SARD-specific autoantibodies; however, when present
as the sole antinuclear antibody (ANA) specificity they tend to
exclude a SARD diagnosis (5–7). This led to the hypothesis that
anti-DFS70/LEDGFp75 autoantibodies could be useful biomark-
ers to exclude a SARD diagnosis, and an algorithm for their clinical
utility has been developed (3, 6, 7). These unique features have
recently attracted much attention, and vigorous efforts to uncover
the significance of this autoantigen–autoantibody system are cur-
rently underway in several laboratories and clinics around the
world.
Anti-DFS70/LEDGFp75 autoantibodies are usually detected
in standard HEp-2 substrates by indirect immunofluorescence
(IIF) microscopy. They are characterized by staining of dense fine
speckles (DFS) in the nucleoplasm of cells in interphase, typi-
cally excluding the nucleolus, with bright staining of metaphase
chromosomes in mitotic cells (Figure 1A). Confirmation of the
specificity of the DFS-IIF pattern for DFS70/LEDGFp75 can be
achieved by examining the sera for reactivity with a protein band
of approximately 70–75 kDa in immunoblots of cell lysates that
express high levels of this protein such as cancer cells (8, 9)
(Figure 1B). Other detection platforms include ELISA and chemi-
luminescence immunoassays such as the Quanta Flash-DFS70
(INOVA Diagnostics).
Distinguishing anti-DFS70/LEDGFp75 autoantibodies from
other common ANAs could be challenging because if examined by
non-expert interpreters in HEp-2 substrates, they could be con-
fused with other nuclear IIF patterns (6). This, combined with the
use of single antibody detection assays, has led to inter-laboratory
variability in reports of the frequencies of anti-DFS70/LEDGFp75
autoantibodies in different populations and patient cohorts. Con-
fusing the DFS-IIF pattern with other ANA patterns may lead to
inaccurate immunodiagnosis of SARD, with ensuing negative con-
sequences for the antibody-positive individuals. Therefore, there is
growing consensus that the ANA test should not be used as the sole
method for the detection of anti-DFS70/LEDGFp75 autoantibod-
ies, and that confirmatory tests are needed until a highly accurate
immunoassay for the detection of these antibodies is developed
and well-validated in multiple laboratories.
Our functional and structural understanding of DFS70/LEDG
Fp75, also known as transcription co-activator p75 and PC4 and
SFRS1 interacting protein 1 (PSIP1), has dramatically increased
since its discovery in the late 1990s. This has led to its emergence as
a stress response transcription co-activator of growing relevance to
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FIGURE 1 | Features of DFS70/LEDGFp75 and its autoantibodies.
(A) Staining pattern of human autoantibodies to DFS70/LEDGFp75 in HEp-2
slides visualized by indirect immunofluorescence (IIF) microscopy. Arrows
point to bright staining in condensed metaphase chromosomes.
(B) Immunoblot showing reactivity of a human serum containing
anti-DFS70/LEDGFp75 autoantibodies against total protein lysates from PC3
prostate cancer cells. A prominent band of approximately 75 kDa was
observed with the serum. Immunoreactivity was detected by enhanced
chemiluminescence. (C) Diagram depicting the main structural domains and
motifs of DFS70/LEDGFp75 with their proposed functions.
human disease, including acquired immunodeficiency syndrome
(AIDS), cancer, and diverse inflammatory conditions (8–11).
However, in spite of the growing knowledge on DFS70/LEDGFp75
biology, we are still perplexed by the relatively common autoan-
tibody response to this protein among ANA-positive patients
who have no clinical evidence of SARD. As briefly discussed
below, we believe that integrating our growing knowledge of this
DFS70/LEDGFp75 with the emerging observations on the clini-
cal contexts in which its associated autoantibodies arise will help
uncover the significance of this autoantigen–autoantibody system.
DFS70/LEDGFp75 STRUCTURE, EXPRESSION, AND
FUNCTIONS
DFS70/LEDGFp75 is a multi-functional protein with well-defined
domains (Figure 1C). Its N-terminal portion encompasses
chromatin-binding elements such as a proline–tryptophan–
tryptophan–proline (PWWP) domain, charged regions (CR), AT-
hook motifs, and a nuclear localization signal (NLS). All these
sequences cooperate to facilitate DFS70/LEDGFp75 binding to
active transcription sites in the chromatin, where it interacts with
RNA polymerase-II transcription complexes to regulate stress
gene expression. The C-terminal portion encompasses a highly
conserved, conformational, and functional domain that contains
the epitope targeted by the autoantibodies (residues 349–435)
(Figure 1C) (12). To date, the functions associated with the
C-terminal portion of DFS70/LEDGFp75 include transcriptional
activity, stress survival activity, and serving as a hub for specific
protein–protein interactions (Figure 1C). The immune targeting
of this functionally important and highly conserved C-terminal
portion of DFS70/LEDGFp75 is consistent with the general-
ized notion that ANA-defined epitopes typically comprise highly
conserved, conformation dependent, functioning sites.
DFS70/LEDGFp75 has a short spliced variant designated
LEDGFp52 that corresponds to its N-terminal residues 1–325
plus eight, intron-derived, unique residues 326–333 [reviewed in
Ref. (10)]. LEDGFp52 is typically not targeted by the autoan-
tibodies and plays roles in transcription and mRNA splicing.
We observed that when overexpressed in cancer cells LEDGFp52
induces apoptosis and antagonizes the transcriptional activity of
DFS70/LEDGFp75 [reviewed in Ref. (10)].
Although originally presumed to be a lens epithelial cell (LEC)
growth factor, compelling evidence indicates that this autoantigen
may not be a growth factor but rather a stress response protein
that is ubiquitously expressed in mammalian cells and tissues,
with overexpression in cancer cells and tumors (8–10, 13). The
Human Protein Atlas lists the PSIP1/LEDGF gene as moderately or
highly expressed, both at the transcript and protein levels, in 80 of
81 non-cancerous tissues analyzed (http://www.proteinatlas.org).
This tissue expression analysis, however, does not distinguish
between the p75 and p52 splice variants.
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DFS70/LEDGFp75 plays a key role in promoting cell survival
in the face of environmental stressors such as alcohol, UVB irra-
diation, serum starvation, and certain viruses and cytotoxic drugs
(9, 10, 13, 14). Ultimately, these stressors lead to increased cellu-
lar oxidative stress, resulting in DFS70/LEDGFp75 activation. The
stress survival functions of DFS70/LEDGFp75 are linked to its abil-
ity to transcriptionally activate stress protective, antioxidant, and
inflammatory genes (10, 13, 14). DFS70/LEDGFp75 contributes
to the activation of these genes by forming complexes with mul-
tiple chromatin-associated proteins. Both the N- and C-terminal
portions of DFS70/LEDGFp75 participate in its transcription and
stress survival functions. The ability of DFS70/LEDGFp75 to pre-
serve the structural integrity of vital cellular organelles such as
the lysosome points to a critical role for this protein in regulating
cellular life and death decisions in response to stress [reviewed in
Ref. (10)]. For additional details on the main cellular functions
ascribed to DFS70/LEDGFp75 please refer to Table 1.
Knockout of the PSIP1/LEDGF gene (which encodes DFS70/
LEDGFp75 and p52) in mice, while not embryonically lethal,
was associated with craniofacial and skeletal abnormalities that
led to premature death in most newborns shortly after birth
due to their inability to nurse, possibly because of olfactory dys-
function or motor abnormalities (15). PSIP/LEDGF−/− knockout
mice that survived to adulthood displayed motor and behav-
ioral defects, craniofacial abnormalities, and eyelid inflammation.
These abnormalities were associated with dysregulation of HOX
genes, many of which were significantly upregulated by the loss
of the PS1P1/LEDGF gene (15). Interestingly, the PS1P1/LEDGF
gene has been mapped to chromosome 9p22.2 region, which is
adjacent to a locus associated with the 9p deletion syndrome, a
rare human chromosomal abnormality characterized by atypical
craniofacial features, inability to nurse and breath, eye diseases,
and several other anomalies. It remains to be determined if loss
of DFS70/LEDGFp75 is a common genetic abnormality in this
syndrome.
DFS70/LEDGFp75 AND HIV/AIDS
DFS70/LEDGFp75 is essential for integration of the human
immunodeficiency virus 1 (HIV-1), a role that is mediated by
its high-affinity interaction with HIV-1 integrase (HIV-IN) (11).
HIV-IN binds to a highly conserved, C-terminal domain of
DFS70/LEDGFp75 mapped to residues 347–429 and named inte-
grase binding domain (IBD) (11). This interaction stabilizes HIV-
IN and contributes to DFS70/LEDGFp75-mediated shuttling of
HIV-1 into the nucleus and tethering it to chromatin to pro-
mote viral integration to transcriptionally active sites. This key
role in HIV-1 integration has catapulted DFS70/LEDGFp75 into
the limelight of promising candidates for therapeutic targeting in
HIV/AIDS (11).
Remarkably, the DFS70/LEDGFp75 autoepitope region
(residues 349–435) is essentially the same region comprised by
the IBD (residues 347–429). While the biological significance
of these “coincidental” findings is unclear, they raise intriguing
questions. Why would an epitope region targeted by autoanti-
bodies be the same region specifically recognized by the HIV-IN?
What elements within this region make it attractive for targeting
by both the immune system and HIV-1? Would the presence of
Table 1 | Key cellular functions of DFS70/LEDGF/p75.
Function Mechanism
Apoptosis
signaling
Cleaved during apoptosis by caspases into fragments
that retain autoepitope and that persist as cells
transition from apoptosis to secondary necrosis; this
cleavage abolishes its pro-survival activities
Cellular stress
survival
Protects mammalian cells against a variety of
environmental stressors (e.g., UVB, oxidative stress,
thermal stress, alcohol, certain drugs)
Chemoresistance Upregulated in chemoresistant cancer cells; promotes
lysosomal stability in the context of drug-induced
caspase-independent cell death
Chromatin
binding
Facilitated by its PWWP domain, AT hooks, and
charged regions
Development Knockout associated with skeletal and craniofacial
abnormalities possibly due to deficient activation of
HOX genes
DNA repair Component of homologous recombination repair
complex
HIV-1 integration Tethers HIV-integrase to transcriptionally active sites
to facilitate integration of HIV-1
Inflammation Implicated in activation of IL6/STAT3 pathway
Leukemogenesis Upregulated in chemoresistant leukemia blasts; binds
to menin-MLL transcription complex to activate
leukemia-associated genes; forms fusion proteins
with NUP98 in some leukemia patients
Malignant
transformation
Overexpressed in cancer cells and certain solid
tumors; promotes cell survival signaling, proliferation,
migration, clonogenicity, angiogenesis, and tumor
growth
Nuclear import Mediated by single classical NLS
Protein–protein
interactions
Binds to several chromatin-associated proteins (e.g.,
HIV-IN, MeCP2, MLL-Menin, JPO2) through its PWWP
and IBD domains
Transcription Interacts with the RNA polymerase-II transcription
complex; contributes to the activation of stress
survival, cancer-associated, inflammation, and HOX
genes; may also act as repressor depending on
context
anti-DFS70/LEDGFp75 autoantibodies, which may absorb extra-
cellularly released DFS70/LEDGFp75, protect individuals against
HIV infection by preventing this protein from binding to HIV-IN?
Studies with cohorts of HIV-positive patients that are susceptible
or resistant to develop full-blown AIDS may provide interesting
insights into the possible relationship between the presence of
these autoantibodies and disease progression.
DFS70/LEDGFp75 AND CANCER
We reported a significantly higher frequency of autoantibodies to
DFS70/LEDGFp75 in prostate cancer patients (PCa) compared
to age- and gender-matched controls [reviewed in Ref. (8, 10)].
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While several groups have recently confirmed this observation in
different PCa cohorts, others have not detected higher frequencies
of these autoantibodies in cancer patients compared to non-cancer
controls (5). It remains to be determined if autoantibodies to
DFS70/LEDGFp75 are more prevalent in PCa patients than in
patients with other cancer types. Toward this goal, it would be
important in future studies to determine the frequency of these
autoantibodies in large cohorts of patients with different cancer
types, individuals at high risk of developing cancer, and matched
controls, using a combination of detection methods.
Our early observation that DFS70/LEDGFp75 is targeted by
autoantibodies in some PCa patients is consistent with our more
recent studies demonstrating its overexpression, both at the tran-
script and protein levels, in PCa tissues (8). This overexpression
has been shown to be statistically significant, typically above a
twofold difference compared to non-malignant tissues, and is
not restricted to PCa since it has been observed in other cancer
types (8, 9). Overexpression of DFS70/LEDGFp75 in malignant
tissues could be induced by increased inflammation and oxida-
tive stress in the microenvironment of the affected tissue, or by
oncogenic viruses such as the human papilloma virus (HPV) (8,
9). A plethora of studies during the past decade by several labora-
tories has provided compelling evidence that when overexpressed
in cancer cells, this autoantigen contributes to the upregulation
and activation of a stress protective pathway that promotes tumor
aggressive properties such as increased cell proliferation and sur-
vival, clonogenicity, migration, angiogenesis, tumor volume, and
selective resistance to chemotherapy-induced cell death (8–10,
14). Thus, DFS70/LEDGFp75 is now considered an emerging
tumor-associated antigen and stress oncoprotein that is relevant
to multiple cancer types.
DFS70/LEDGFp75 AND EYE DISEASES
Several studies have reported an association of anti-
DFS70/LEDGFp75 autoantibodies with diverse inflammatory
diseases of the eye including cataracts associated with atopic
dermatitis, Vogt–Koyanagi–Harada (VKH) disease, sympathetic
ophthalmia, Behcet’s disease, and atypical retinal degeneration
[reviewed in Ref. (2, 10, 13)]. Notably, the original cDNA encoding
the LEDGFp75 protein was identified from the screening of a lens
epithelium-derived cDNA library using a serum from a patient
with age-related cataract (13).
Anti-DFS70/LEDGFp75 antibodies (both human and rabbit)
appear to have cytotoxic properties in LECs grown in vitro, sug-
gesting a pathogenic role for the autoantibodies in the context of
eye disease [reviewed in Ref. (13)]. While the mechanism of cyto-
toxicity was not clear, it was proposed that the antibodies bind
to DFS70/LEDGFp75 released into the extracellular environment,
preventing its re-entry into LECs where it acts as a pro-survival fac-
tor. It remains to be established, however, if these cytotoxic prop-
erties are specific for LECs since they have not been documented
in other cellular or tissue models.
DFS70/LEDGFp75 has been shown to protect eye cells from
various environmental stressors through the transcriptional acti-
vation of stress genes (13). It would be important, how-
ever, to determine in future studies if the humoral response
to DFS70/LEDGFp75 in eye diseases or other inflammatory
pathologies reflects an aberrant expression or function of this
protein in the diseased tissue as a consequence of exposure to
environmental stressors.
WHAT ARE THE AUTOANTIBODIES TO DFS70/LEDGFp75
TRYING TO TELL US?
This question, first posed by our group a decade ago (2), is still
elusive. In spite of the wealth of information on the biology
and clinical associations of the DFS70/LEDGFp75 autoantibody–
autoantigen system that has accumulated during the past 15 years,
we still lack a clear understanding of this system. We suggest,
however, that in our quest to elucidate the biological and clinical
significance of humoral autoimmunity to anti-DFS70/LEDGFp75,
we should take into account the following key observations:
(1) The nuclear DFS-IIF pattern produced by anti-DFS70/LEDG
Fp75 autoantibodies is the most common ANA pattern in sera
from patients with non-SARD diagnosis referred to clinical
diagnostic laboratories (4, 5).
(2) Anti-DFS70/LEDGFp75 autoantibodies can be found in
patients with diverse inflammatory conditions such as atopic
dermatitis, alopecia areata, interstitial cystitis, asthma, pedi-
atric chronic fatigue syndrome, miscellaneous non-SARD
autoimmune and inflammatory diseases, eye diseases, and
prostate cancer (1–7, 10). With a few exceptions, their fre-
quency in these non-SARD inflammatory conditions usually
ranges from 6 to 20%.
(3) These autoantibodies are typically IgG and can circulate
at high titers, often reaching 1:5,120, in some “apparently
healthy” individuals who stay healthy after years of follow up
(6). This could suggest that they are natural antibodies.
(4) The C-terminal autoepitope targeted by anti-DFS70/LEDG
Fp75 autoantibodies is a highly conserved, conformational,
and functional region that serves as a hub for interactions
with several chromatin-associated proteins (10–12).
(5) DFS70/LEDGFp75 is upregulated in a variety of cells and
tissues in response to environmental stressors (e.g., UVB,
hyperthermia, starvation, viral infections, cytotoxic drugs,
etc.) and promotes cell survival by engaging in multiple
complexes in the chromatin and transcriptionally activating
stress protective, antioxidant, and inflammation-related genes
(8–10, 13, 14).
(6) DFS70/LEDGFp75 is cleaved by caspases during apopto-
sis into fragments that contain the C-terminal autoepitope
(2, 10).
We speculate that aberrant tissue manifestations of this
autoantigen (i.e., overexpression, extracellular release, cell death
cleavage, induction by viruses) under stressful and pro-
inflammatory conditions could alter its immunogenicity, leading
to the elicitation of the autoantibodies in susceptible individuals.
For instance, the dynamic functions of the autoepitope domain
of DFS70/LEDGFp75, which include interactions with multiple
self- and non-self proteins to form shifting chromatin-associated
complexes depending on cellular/molecular context, may influ-
ence its immunogenicity under inflammatory conditions, leading
to autoimmune targeting. We reported previously that cleaved
forms of this protein generated during apoptosis and persist-
ing through secondary necrosis have a disrupted C-terminus that
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retains the autoepitope [reviewed in Ref. (2, 10)]. These aberrant
forms of DFS70/LEDGFp75 enhance stress-induced cell death and
may also exhibit increased immunogenicity in the context of tissue
damage and inflammatory cell death. The extracellular release of
DFS70/LEDGFp75, observed in LECs (13), could also make this
protein the target of a humoral immune response if this release
occurs in a pro-inflammatory microenvironment.
Depending on the context in which they arise, anti-DFS70/
LEDGFp75 autoantibodies could play various roles. They may
serve a protective role by removing DFS70/LEDGFp75 and its
cleavage fragments from cellular debris generated during non-
inflammatory apoptotic cell death. They could also play a patho-
genic role by binding to extracellularly released DFS70/LEDGFp75
and preventing it from entering cells where it could activate a stress
survival pathway. However, it would be fascinating to determine
if autoantibody-mediated removal of DFS70/LEDGFp75 from
extracellular circulation in the context of cancer or HIV infection
could confer a protective advantage to patients due to the blockade
of its pro-tumorigenic or HIV-IN binding functions, respectively,
by the antibodies. These autoantibodies might also act as “sensors”
or “reporters” of underlying, non-SARD inflammatory conditions
associated with increased oxidative stress and aberrant expression
or functions of DFS70/LEDGFp75 that alter its immunogenicity
(10). Their presence in susceptible, “apparently healthy” individ-
uals could be indicative of an undetected chronic inflammatory
response.
It is plausible that these antibodies could be triggered by
unidentified environmental factors. The recent observation that
HPV activates DFS70/LEDGFp75 (9) raises the intriguing possi-
bility that HPV vaccination or infection may be associated with
overexpression of this autoantigen in a pro-inflammatory context.
This could not only influence its cellular functions but also its
immunogenicity.
CONCLUSION
A better understanding of the context in which anti-DFS70/
LEDGFp75 autoantibodies arise will require not only increased
knowledge on DFS70/LEDGFp75 biology but also comprehensive
information on individuals that test positive for these autoanti-
bodies. This should include age, gender, health history, vaccination
record, lifestyle, ethnicity, geographic location, and exposure to
environmental stressors or xenobiotics. This might help deter-
mine if the presence of these autoantibodies could be linked to
specific environmental factors that may influence the levels of
oxidative stress in a particular tissue microenvironment, lead-
ing to tissue damage, altered DFS70/LEDGFp75 expression or
function, and enhanced immunogenicity of this protein under
pro-inflammatory conditions.
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